发现MET驱动的单基因型脂肪性肝病病因
研究在一个家族性代谢功能障碍相关脂肪性肝炎病例中发现MET基因变异,通过蛋白建模、动力学和细胞实验进行功能验证,并在3904例脂肪性肝病患者的外显子组测序数据中筛查确认该变异为单基因病因,同时检出其他罕见可能致病的MET变异。
要点
- MET基因NM_000245.4:c.3505A>T;p.(Ile1169Phe)变异被功能验证为脂肪性肝病的单基因病因。
- 3904例脂肪性肝病患者中1.1%(45/3904)携带罕见预测致病MET变异。
- 45例中8例(17.7%)的MET激酶域预测致病变异功能上类似家族病例变异。
核心结论
- 研究首次报道生殖细胞非恶性罕见MET驱动疾病,即一种单基因型脂肪性肝病。
研究设计与样本
- 研究对一个家族性代谢功能障碍相关脂肪性肝炎病例进行深度变异功能分析,包括蛋白建模、动力学和细胞实验。
- 分析3904例脂肪性肝病患者的外显子组测序数据以识别额外病例并建立特定基因变异与脂肪性肝病诊断的关联。
主要发现
- 发现并功能验证MET激酶域NM_000245.4:c.3505A>T;p.(Ile1169Phe)变异为脂肪性肝病的单基因病因。
- 通过筛查测序数据检出额外的超罕见、既往未解读且可能致病的MET变异。
- 基于电子病历回顾确认脂肪性肝病的个体中,1.1%(45/3904)携带罕见预测致病MET变异。
- 45例中8例(17.7%)的MET激酶域预测致病变异经确认功能上类似家族病例变异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease affects about a third of adults worldwide and is projected soon to be the leading cause of liver cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction-associated steatohepatitis, liver cirrhosis, and HCC. Metabolic dysfunction-associated steatotic liver disease pathogenesis is believed to involve a combination of genetic and environmental risk factors. Single nucleotide polymorphisms have been implicated, but non-syndromic monogenic causes are lacking. APPROACH AND RESULTS: We identified a novel genetic variant in a familial case of metabolic dysfunction-associated steatohepatitis and performed deep variant functional analysis, including protein modeling, dynamics, and cell-based assays to assess molecular mechanisms of dysfunction and altered cellular signaling. We analyzed exome sequencing data of 3904 individuals with steatotic liver disease (SLD) to identify additional cases and establish the link between specific gene variants and SLD diagnosis. We discovered and functionally validated the NM_000245.4:c.3505A>T; p.(Ile1169Phe) variant in the MET (mesenchymal-epithelial transition) kinase domain as a monogenic cause of SLD. Subsequently, we detected additional ultra-rare, previously uninterpreted, and likely deleterious variants in MET from screening sequencing data. Among individuals with confirmed SLD based on electronic record review, 1.1% (45/3904) had rare predicted deleterious MET variants. Eight of 45 (17.7%) individuals had predicted deleterious variants in the MET kinase domain confirmed to be functionally like the familial case variant. CONCLUSIONS: We report the first germline nonmalignant rare MET -driven disease, a monogenic form of SLD.
引用
- Pinto E Vairo F, Zimmermann MT, Wagenknecht J, et al. Discovery of a MET -driven monogenic cause of steatotic liver disease. Hepatology. 2025. PMID: 39879586. doi:10.1097/HEP.0000000000001249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。